Human Papillomavirus (HPV) Technology Validation Study for the the ABBOTT Alinity HPV testing platform comparing the accuracy of HPV testing using a self-collected swab sample, with using a sample taken by a clinician using a liquid-based cytology sample, for adult participants undergoing cervical cancer screening in New Zealand.
Not Applicable
Completed
- Conditions
- Cervical cancer screeningCancer - Cervical (cervix)
- Registration Number
- ACTRN12623000962639
- Lead Sponsor
- ational Cervical Screening Programme ( NCSP)
- Brief Summary
The trial outcomes confirm the validity of using an self-collected vaginal swab sample to test for any high-risk type of HPV, as well as HPV 16, HPV 18 or HPV Other separately, (as will be used in the New Zealand HPV primary screening programme) when analysed at Awanui Laboratories Dunedin (formerly known as SCL) using the ABBOTT Alinity HPV testing platform.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 348
Inclusion Criteria
This is a pragmatic study and all people attending the public hospital colposcopy clinic will be invited to participate.
Exclusion Criteria
Those who choose not to participate or who are unable to give informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method